Company intelligence / Profile preview

Hunazine Biotech

Cartagena, Murcia, Spainhunazinebiotech.com ↗

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Hunazine Biotech S.L. is a Spanish biotech company focused exclusively on developing novel treatments for cholera and severe diarrheal diseases. Its lead asset, VR‑AD‑1005, a small molecule licensed from Vanessa Biotech, has advanced to Phase 2 clinical trials targeting symptomatic relief in cholera patients by reducing stool volume without affecting gut motility or causing constipation. The company claims this approach addresses the challenge of convective washout that limits efficacy of current antidiarrheals in acute watery diarrhea.

Therapeutic areas: GastroenterologyRare DiseasesInfectious Diseases
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

2 assets

VR-AD-1005

1 more asset in the full pipeline.

Partnerships

Licensed key assets from Vanessa Biotech/Vanessa Research Inc.

Beyond the preview

Go deeper on Hunazine Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hunazine Biotech.